Last reviewed · How we verify
NCT04982055
Intravenous Versus Subcutaneous Administration of Low Molecular Weight Heparin for Thromboprophylaxis in Critically Ill Patients
Phase 4 trial testing Nadroparin (intravenous Infusion) in Critical Illness in 60 participants. Completed in 31 December 2020.
31 December 2020
Quick facts
| Lead sponsor | Clinique Saint Pierre Ottignies |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 60 |
| Start date | 8 April 2015 |
| Primary completion | 31 December 2020 |
| Estimated completion | 31 December 2020 |
Drugs / interventions tested
- Nadroparin (intravenous Infusion) — full drug profile →
- Nadroparin (subcutaneous group) — full drug profile →
Conditions studied
- Critical Illness — all drugs for Critical Illness →
Sponsor
Clinique Saint Pierre Ottignies — full company profile →
Who can join
18 and older, any sex, with Critical Illness. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Objective: To compare the pharmacokinetic profiles of intravenous versus subcutaneous route of administration of LMWH for thromboprophylaxis in critically ill patients
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Pharmacokinetic profiles of intravenous versus subcutaneous administration of low molecular weight heparin for thromboprophylaxis in critically ill patients: A randomized controlled trial.
De Schryver N, Serck N, Eeckhoudt S, Laterre PF, et al · · 2022 · cited 3× · PMID 35381407 · DOI 10.1016/j.jcrc.2022.154029
Verify or expand the search:
- PubMed search for NCT04982055
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Critical Illness
Currently open trials in the same condition.
- NCT06189924 — Exhaled Breath Condensate Analysis in Mechanically Ventilated Patients · recruiting
- NCT07418242 — Prognostic Value of Novel Biomarkers on Adverse Renal Outcomes in High-Risk Cardiac Surgery Patients · recruiting
- NCT07101640 — PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysp · Phase 1, PHASE2 · recruiting
- NCT07177183 — Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure · NA · recruiting
- NCT07369258 — Clinical Application of Listening to Music to Prevent Delirium in the Intensive Care Unit · NA · recruiting
Other Clinique Saint Pierre Ottignies trials
Trials by the same sponsor.
- NCT07384598 — Pharmacokinetic Profiles of Subcutaneous Enoxaparin for Thromboprophylaxis in Critically Ill Patients With Renal Failure · NA · not yet recruiting
- NCT04401228 — Predictive Models for Intensive Care Admission and Death of COVID-19 · unknown
- NCT04403360 — Erector Spinae Plane Block After Lumbar Spinal Stenosis Surgery · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04982055 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Clinique Saint Pierre Ottignies
- Last refreshed: 29 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04982055.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing